Haohai Biotec Discloses CSRC Penalty Against Controlling Shareholder for Unrelated Insider Trading Case

Claim 70% Off TipRanks This Holiday SeasonUnlock hedge-fund level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialShanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) has provided an update. Shanghai Haohai Biological Technology has disclosed that one of its controlling shareholders and de facto controllers, Mr. Jiang Wei, has received an administrative penalty decision from the China Securities Regulatory Commission relating to insider trading and recommending securities trades to others, in matters explicitly stated as unrelated to the company. The CSRC has ordered the confiscation of approximately RMB4.71 million in alleged illegal gains and imposed a fine of about RMB14.63 million on Mr. Jiang, and while the announcement emphasizes that the case does not concern the company’s operations, it nonetheless underscores governance and regulatory scrutiny surrounding key shareholders, which may be closely watched by investors and other stakeholders. The most recent analyst rating on (HK:6826) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page. More about Shanghai Haohai Biological Technology Co., Ltd. Class H Shanghai Haohai Biological Technology Co., Ltd. is a China-based biopharmaceutical company listed in both Shanghai and Hong Kong, engaged in the research, development and production of biomedical and regenerative products. The company focuses on medical devices and biological materials, serving healthcare markets that require advanced surgical, ophthalmic, and aesthetic solutions. Average Trading Volume: 216,606 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$10.6B Learn more about 6826 stock on TipRanks’ Stock Analysis page.